Act Capital Management, LLC Kazia Therapeutics LTD Transaction History
Act Capital Management, LLC
- $72.5 Million
- Q3 2022
Shares
2 transactions
Others Institutions Holding KZIA
# of Institutions
21Shares Held
2.13MCall Options Held
93.2KPut Options Held
0-
Mai Capital Management1.36MShares$4.24 Million0.01% of portfolio
-
Ubs Group Ag249KShares$775,7950.0% of portfolio
-
Morgan Stanley New York, NY220KShares$685,0110.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il60.5KShares$188,0800.0% of portfolio
-
Jane Street Group, LLC New York, NY46.1KShares$143,4020.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $47M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...